GlassScriptPhysician profile
Daniela M Sikoski
NPI 1932160215
$2,945.25
in general payments reported to CMS, 2019-2025
29 companies · $486 in 2025
The $486 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $441 · 2020: $162 · 2021: $521 · 2022: $623 · 2023: $492 · 2024: $220 · 2025: $486.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,198.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,198.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $548.01 | 2019-2025 | Repatha, Otezla, Evenity |
| Abbvie INC. | $361.06 | 2021-2025 | Ubrelvy, Synthroid, Qulipta |
| Novo Nordisk INC | $233.68 | 2022-2025 | Ozempic, Wegovy |
| Boston Scientific Corporation | $192.12 | 2021-2022 | |
| Glaxosmithkline, LLC. | $191.81 | 2020-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novartis Pharmaceuticals Corporation | $179.53 | 2019-2023 | |
| Edwards Lifesciences Corporation | $131.44 | 2023 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Pfizer INC. | $126.31 | 2019-2025 | |
| W. L. Gore & Associates, INC. | $112.93 | 2019 | |
| Esperion Therapeutics, INC. | $110.05 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $109.22 | 2019-2025 | Airsupra |
| Takeda Pharmaceuticals U.S.A., INC. | $70.67 | 2020-2022 | |
| Astellas Pharma US INC | $60.80 | 2020-2023 | Veozah |
| Lilly USA, LLC | $60.74 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $55.21 | 2019-2020 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $54.43 | 2019 | |
| Insulet Corporation | $46.81 | 2021-2022 | |
| Mylan Specialty L.P. | $43.96 | 2021-2022 | |
| Ibsa Pharma INC. | $33.86 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $32.61 | 2019 | |
| Amarin Pharma, INC. | $32.23 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.46 | 2022 | |
| Nevro Corp. | $26.75 | 2024 | Senza |
| Merck Sharp & Dohme LLC | $19.16 | 2023 | Pneumovax 23, Gardasil 9, Vaxneuvance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $18.59 | 2019 | |
| Allergan, INC. | $16.81 | 2019 | |
| Bausch Health US, LLC | $16.15 | 2019 | |
| Ironwood Pharmaceuticals, INC | $14.45 | 2022 | |
| Idorsia Pharmaceuticals US INC | $14.40 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniela Sikoski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.